Company / Net Income
Royalty Pharma plc Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$770.9M
FY2025
5-year range
$770.9M / $2.3B
FY2021-FY2025
Trend
-10.2%
vs FY2024
Sector context
#19 of 216
Health Care
What the data says
Among 216 Health Care companies, Royalty Pharma plc is in the top 9% for net income. Net Income has fluctuated over the past 8 years, ranging from $771M in FY2025 to $2.3B in FY2021.
Based on SEC 10-K filings.
$771M in FY2025 with a 5-year CAGR of -11.0%. Top quartile in the Health Care sector.
Declined from $1.1B to $771M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -7.5%
- 5-Year CAGR
- -11.0%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 216This company $770.9M Sector average $454.1M
▼
+69.8% above sector average
Key checks
Key Insights
- 5-year CAGR of -11.0%, indicating a declining trend.
- In FY2025, net income decreased 10.2% year-over-year.
- Ranks #19 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $770.9M | -10.2% |
| FY2024 | $859.0M | -24.3% |
| FY2023 | $1.1B | +16.4% |
| FY2022 | $975.0M | -58.5% |
| FY2021 | $2.3B | +70.5% |
| FY2020 | $1.4B | -41.3% |
| FY2019 | $2.3B | +70.5% |
| FY2018 | $1.4B | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026